SLC2A5 and cancer: Furthering our understanding of fluorescent probes like NBDM will expedite the development of Glut5-specific PET compounds which could be non-invasive tools for determining Glut5 expression in vivo and provide a means for monitoring the onset and progression of metabolic syndrome and aggressive cancers.